BLUE Bluebird stock Story

BLUE -  USA Stock  

USD 33.15  0.17  0.52%

It looks as if Bluebird Bio may not have a good chance to recover from the latest dip as its shares fell again. The company's current daily volatility is 2.57 percent, with a beta of 0.58 and an alpha of -0.22 over DOW. As some shareholders are moving away from the latest market volatility surge, we are going to digest Bluebird Bio based on how it reacts to economic swings. We will evaluate why we are still optimistic in anticipation of a recovery.
Published over six months ago
View all stories for Bluebird Bio | View All Stories
How risky is Bluebird Bio after the latest volatility surge?
Bluebird Bio currently holds roughly 1.55 B in cash with (438.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.4. Our investment recommendation tool can be used to complement Bluebird Bio trade advice provided by experts. It analyzes the company's potential to grow against your specific risk preferences and investment horizon.
Investing in Bluebird Bio, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Bluebird Bio along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Bluebird Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Bluebird Bio in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Bluebird Bio. Your research has to be compared to or analyzed against Bluebird Bio's peers to derive any actionable benefits. When done correctly, Bluebird Bio's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Bluebird Bio.

How important is Bluebird Bio's Liquidity

Bluebird Bio financial leverage refers to using borrowed capital as a funding source to finance Bluebird Bio ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Bluebird Bio financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Bluebird Bio's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Bluebird Bio, but it might be worth checking our own buy vs. sell analysis

Bluebird Bio Correlation with Peers

Investors in BLUE Bluebird can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Bluebird Bio. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Bluebird Bio and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities BLUE Bluebird is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of BLUE Bluebird for more details

Detailed Outlook On Bluebird Bio

Bluebird Bio secures Sharpe Ratio (or Efficiency) of -0.11, which signifies that the company had -0.11% of return per unit of risk over the last month. Macroaxis standpoint towards foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Bluebird Bio exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Bluebird Bio risk adjusted performance of (0.09), and Mean Deviation of 1.95 to double-check the risk estimate we provide.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Another small dip for Bluebird Bio

Latest coefficient of variation is at -1183.93. As of the 31st of October, Bluebird Bio shows the risk adjusted performance of (0.09), and Mean Deviation of 1.95. Bluebird Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed nineteen technical drivers for Bluebird Bio, which can be compared to its rivals. Please confirm Bluebird Bio variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if Bluebird Bio is priced correctly, providing market reflects its regular price of 51.71 per share. Given that Bluebird Bio has jensen alpha of (0.22), we suggest you to validate Bluebird Bio's prevailing market performance to make sure the company can sustain itself at a future point.

Our Final Perspective on Bluebird Bio

Although many other companies in the biotechnology industry are either recovering or due for a correction, Bluebird Bio may not be performing as strong as the other in terms of long-term growth potentials. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Bluebird as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Bluebird Bio.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Bluebird Bio. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to